Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Angiogenesis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLXNB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLXNB1 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View PLXNB1 Products |
| Gene Delivery | PLXNB1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based conformation-sensitive assays. |
View PLXNB1 Products |
| Benchmark Ab | Anti-PLXNB1 Recombinant Antibody Recombinant positive control derived from public patent sequences. |
View PLXNB1 Products |
| Validator | PLXNB1 siRNA Set For target knockdown verification and phenotypic validation. |
View PLXNB1 Products |
| Related Target A | SEMA4D Primary high-affinity ligand for PLXNB1; essential for ligand-blocking and functional assay development. |
View SEMA4D Products |
| Related Target B | PLXNB2 Plexin subfamily homolog; critical for specificity profiling and eliminating off-target cross-reactivity. |
View PLXNB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SEMA4D-binding blockade validation | HEK293 expressed PLXNB1 ECD-Fc with native glycosylation ensuring correct folding and ligand interaction |
| Subfamily counter screening | Homolog panel including PLXNB2 and PLXNB3 recombinant proteins strictly verified by mass spectrometry |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included |
| False Positives in Phenotypic Assays | Validated siRNA pool included for target-specific knockdown verification |
Live PLXNB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLXNB1 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to antibody-drug conjugates (ADCs) and bispecific constructs targeting the SEMA4D-PLXNB1 signaling axis. As first-generation therapies targeting the ligand (SEMA4D) reach late-stage clinical evaluation, the next wave of R&D is directly targeting the receptor, PLXNB1, to block tumor cell migration, invasive growth, and angiogenesis in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech & Academic Collaborations | Prostate Cancer, Breast Cancer, Melanoma | Internalization Assay (Requires high-purity ECD-Fc for binding and lentivirus for stable cell lines) |
| Bispecific Antibody | Translational Oncology Companies | Metastatic Solid Tumors | Dual-binding validation (Requires highly pure PLXNB1 and co-target proteins) |
| Small Molecule Inhibitors | Preclinical Discovery Programs | Angiogenesis-driven Cancers | Selectivity profiling against Plexin subfamily (Requires PLXNB1 vs PLXNB2 mutant/WT panels) |